title: Changes in peripheral blood immune cells: their prognostic significance in metastatic renal cell carcinoma patients treated with molecular targeted therapy.
abstract: Recently, novel molecular targeted agents markedly changed the treatment of renal cell carcinoma (RCC), with promising results. However, there is little understanding of how these agents affect immune cell populations in RCC, an immunogenic tumor. Therefore, we investigated the changes in the peripheral blood immune cells in 58 RCC patients during the first 4 weeks of treatment with sorafenib, sunitinib, everolimus, or temsirolimus and evaluated whether these changes were associated with clinical outcomes. The immunological parameters were the proportion of type-1 (Th1) and type-2 (Th2) T cells, regulatory T cells (Treg), mature dendritic cells, and the neutrophil-to-lymphocyte ratio (NLR). The changes in these immune cells varied with the agents and the clinical response, dichotomized by the median progression-free survival (PFS) time (PFS-short or PFS-long). A significant decrease in the Th1/Th2 ratio was seen after sunitinib treatment only in the PFS-short group, suggesting a shift toward Th2 that down-regulates host immunity. The NLRs indicative of the balance between host immunity and cancer-related inflammation were consistently lower in the PFS-long group than in the PFS-short group, suggesting that lower NLR is associated with better clinical response. Only sunitinib decreased NLR remarkably regardless of PFS status, which may favor anti-tumor immunity. When patients were dichotomized by the cutoff values, Th1/Th2 ratio was not associated with PFS in any targeted therapy, while lower pre-treatment NLR was associated with longer PFS in each targeted therapy. In addition, in RCC patients given sequential targeted therapy, those with a lower baseline NLR survived significantly longer compared with the counterparts. Moreover, those whose baseline NLR was sustained low during the initial therapy survived the longest. Our results suggest the diverse changes in host immune cells in RCC patients during targeted therapy. The changes in NLR during the early phase of targeted therapy may be a powerful discriminator of who will benefit from the subsequent treatment.
authors.affiliation: Department of Urology, Jichi Medical University, 3311-1 Yakushiji, Shimotsukeshi, Tochigi, Japan. minoruk@jichi.ac.jp
authors.forename: Minoru
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Taro
authors.initials: T
authors.lastname: Kubo
authors.forename: Kenji
authors.initials: K
authors.lastname: Komatsu
authors.forename: Akira
authors.initials: A
authors.lastname: Fujisaki
authors.forename: Fumihito
authors.initials: F
authors.lastname: Terauchi
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Natsui
authors.forename: Akinori
authors.initials: A
authors.lastname: Nukui
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Kurokawa
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Morita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects* / Q000276:immunology; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D011379:Prognosis; D018417:Th1 Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome
references.citation: Cancer Immunol Immunother. 2009 Jan;58(1):15-23
references.pmid: 18414853
references.citation: Clin Cancer Res. 2005 Dec 1;11(23):8326-31
references.pmid: 16322292
references.citation: World J Gastroenterol. 2006 May 28;12(20):3275-82
references.pmid: 16718852
references.citation: Cancer Immunol Immunother. 2007 Nov;56(11):1743-53
references.pmid: 17487490
references.citation: Clin Cancer Res. 1997 Mar;3(3):483-90
references.pmid: 9815709
references.citation: N Engl J Med. 2007 Jan 11;356(2):115-24
references.pmid: 17215529
references.citation: Nature. 2008 Jul 24;454(7203):436-44
references.pmid: 18650914
references.citation: Eur Urol. 2007 Jan;51(1):168-73; discussion 174
references.pmid: 16844285
references.citation: Clin Dev Immunol. 2012;2012:607851
references.pmid: 22666283
references.citation: Angiogenesis. 2003;6(4):283-7
references.pmid: 15166496
references.citation: BJU Int. 1999 Mar;83(4):488-92
references.pmid: 10210576
references.citation: J Clin Invest. 2007 May;117(5):1167-74
references.pmid: 17476346
references.citation: J Surg Oncol. 2005 Sep 1;91(3):181-4
references.pmid: 16118772
references.citation: Br J Cancer. 2005 Aug 8;93(3):273-8
references.pmid: 16052222
references.citation: J Exp Med. 1996 Jan 1;183(1):87-97
references.pmid: 8551248
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):902-11
references.pmid: 17289884
references.citation: J Urol. 2007 Nov;178(5):1883-7
references.pmid: 17868732
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Br J Cancer. 2003 Oct 20;89(8):1463-72
references.pmid: 14562018
references.citation: BJU Int. 2007 Jan;99(1):77-80
references.pmid: 16956357
references.citation: Oncology. 2007;73(3-4):215-20
references.pmid: 18424885
references.citation: J Urol. 2010 Sep;184(3):873-8
references.pmid: 20643463
references.citation: J Clin Oncol. 2006 Dec 1;24(34):5373-80
references.pmid: 17135638
references.citation: Curr Opin Immunol. 2004 Feb;16(1):21-5
references.pmid: 14734106
references.citation: J Urol. 2013 Feb;189(2):454-61
references.pmid: 23041457
references.citation: Clin Cancer Res. 2002 Jun;8(6):1787-93
references.pmid: 12060618
references.citation: BJU Int. 2009 Feb;103(3):399-405
references.pmid: 19021626
references.citation: Br J Cancer. 2007 Jun 18;96(12):1888-95
references.pmid: 17505508
references.citation: J Clin Oncol. 1999 Aug;17(8):2530-40
references.pmid: 10561319
references.citation: J Clin Oncol. 2009 Dec 1;27(34):5794-9
references.pmid: 19826129
references.citation: Clin Cancer Res. 2008 Oct 15;14(20):6674-82
references.pmid: 18927310
references.citation: Cancer. 2009 May 15;115(10 Suppl):2298-305
references.pmid: 19402060
references.citation: Cancer J Sci Am. 2000 Feb;6 Suppl 1:S55-7
references.pmid: 10685660
references.citation: J Immunol. 2010 Mar 15;184(6):3106-16
references.pmid: 20142361
references.citation: Nat Rev Immunol. 2004 Dec;4(12):941-52
references.pmid: 15573129
references.citation: Cancer Biother Radiopharm. 2008 Feb;23(1):129-34
references.pmid: 18298337
references.citation: Cancer. 2002 Sep 1;95(5):1045-50
references.pmid: 12209689
references.citation: Clin Cancer Res. 2003 Feb;9(2):606-12
references.pmid: 12576425
references.citation: J Clin Oncol. 2006 May 1;24(13):1997-2005
references.pmid: 16648500
references.citation: Blood. 2008 Jun 15;111(12):5610-20
references.pmid: 18310500
references.citation: J Immunol. 1998 Jun 15;160(12):5869-73
references.pmid: 9637498
references.citation: Anticancer Res. 2007 Jan-Feb;27(1A):165-73
references.pmid: 17352228
references.citation: Annu Rev Immunol. 1989;7:145-73
references.pmid: 2523712
references.citation: J Immunol Methods. 1993 Feb 26;159(1-2):197-207
references.pmid: 8445253
references.citation: Lancet. 2008 Aug 9;372(9637):449-56
references.pmid: 18653228
references.citation: Cancer. 2007 Aug 1;110(3):543-50
references.pmid: 17577222
references.citation: Eur J Cancer. 2012 Jan;48(2):202-8
references.pmid: 22018713
references.citation: Am J Pathol. 1998 Jan;152(1):83-92
references.pmid: 9422526
references.citation: J Immunol. 1997 Apr 1;158(7):3359-65
references.pmid: 9120294
references.citation: Clin Genitourin Cancer. 2013 Jun;11(2):141-8
references.pmid: 23083797
references.citation: N Engl J Med. 2007 May 31;356(22):2271-81
references.pmid: 17538086
references.citation: Lancet. 2011 Dec 3;378(9807):1931-9
references.pmid: 22056247
references.citation: N Engl J Med. 2007 Jan 11;356(2):125-34
references.pmid: 17215530
references.citation: J Urol. 2005 Jan;173(1):52-5
references.pmid: 15592024
references.citation: Clin Cancer Res. 2008 Sep 15;14(18):5884-92
references.pmid: 18794101